Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib (“Iressa”)‐sensitive and resistant xenograft models

Fumiko Taguchi(National Cancer Research Institute), Kazuto Nishio(Kindai University)

Cancer Science

December 1, 2004

10.1111/j.1349-7006.2004.tb03187.x

Cited by 60

Related Papers

Activin A inhibits vascular endothelial cell growth and suppresses tumour angiogenesis in gastric cancer

|British Journal of Cancer|2011|110

Gene amplification of EGFR, HER2, FGFR2 and MET in esophageal squamous cell carcinoma

|International Journal of Oncology|2013|91

Detection of the T790M mutation of <i>EGFR</i> in plasma of advanced non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR study)

|Oncotarget|2016|72

Hypoxia induces resistance to ALK inhibitors in the H3122 non-small cell lung cancer cell line with an ALK rearrangement via epithelial-mesenchymal transition

|International Journal of Oncology|2014|56

Overexpression of heparan sulfate 6-O-sulfotransferase-2 in colorectal cancer

|Molecular and Clinical Oncology|2013|38